Legend Biotech (LEGN) Cash & Equivalents (2019 - 2025)

Legend Biotech's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $901.9 million for Q4 2025.

• Quarterly Cash & Equivalents rose 214.58% year-over-year to $901.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $901.9 million (up 214.58% YoY) and the FY2025 annual result came in at $901.9 million, up 214.58% from the prior year.
• Cash & Equivalents was $901.9 million for Q4 2025 at Legend Biotech, up from $278.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q4 2023 and bottomed at $201.3 million in Q2 2024.
• A 5-year average of $607.6 million and a median of $473.7 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 224.72% — and 2024, when it slumped 83.68%.
• Legend Biotech's Cash & Equivalents stood at $688.9 million in 2021, then grew by 14.09% to $786.0 million in 2022, then soared by 62.55% to $1.3 billion in 2023, then sank by 77.56% to $286.7 million in 2024, then soared by 214.58% to $901.9 million in 2025.
• Business Quant data shows LEGN's Cash & Equivalents at $901.9 million in Q4 2025, $278.9 million in Q3 2025, and $266.6 million in Q2 2025.